{"disease":{"id":"advanced-head-and-neck-carcinoma","name":"advanced head and neck carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04949503","title":"A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN","phase":"","overall_status":"COMPLETED","enrollment_count":1931,"lead_sponsor_name":"Biotech Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05050162","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":1714,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06129864","title":"A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1145,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT04892173","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Johnson & Johnson Enterprise Innovation Inc.","has_results":false},{"nct_id":"NCT07524452","title":"Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Ming-Yuan Chen","has_results":false},{"nct_id":"NCT02526017","title":"Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04215978","title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT07583316","title":"A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Corregene Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT05094804","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT03117257","title":"Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":144,"lead_sponsor_name":"Guiyang Medical University","has_results":false},{"nct_id":"NCT06258811","title":"Neoadjuvant Immunochemotherapy for LAOSCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Lai-ping Zhong","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03196869","title":"the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Guiyang Medical University","has_results":false},{"nct_id":"NCT03426657","title":"Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT06470217","title":"Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03665285","title":"A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"NextCure, Inc.","has_results":true},{"nct_id":"NCT06240689","title":"A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05635643","title":"Study of CHS-114 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Coherus Oncology, Inc.","has_results":false},{"nct_id":"NCT02565758","title":"ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04491942","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06147037","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05156060","title":"Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Natalie Lockney","has_results":false},{"nct_id":"NCT07242365","title":"Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07369882","title":"Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Qunxing Li,MD","has_results":false},{"nct_id":"NCT03666273","title":"Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04397341","title":"Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT03684785","title":"Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Exicure, Inc.","has_results":false},{"nct_id":"NCT05115760","title":"Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05039801","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04383210","title":"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"Elevation Oncology","has_results":true},{"nct_id":"NCT04442126","title":"A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Numab Therapeutics AG","has_results":true},{"nct_id":"NCT02955290","title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05172245","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07379424","title":"A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":37,"lead_sponsor_name":"chen chao Professor","has_results":false},{"nct_id":"NCT03841110","title":"FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}